EpiFinder™ cNUC
Unmatched Epigenomic Insights Directly From Liquid Biopsy
Liquid biopsies offer minimally invasive access to real‑time disease biology, but most technologies capture only genetic information and overlook the regulatory context encoded in circulating nucleosomes. EpiFinder™ cNUC is the first product enabling direct, multiplexed epigenomic profiling of plasma and serum, delivering powerful biomarker insights into epigenetic signatures associated with disease state, progression, and treatment response.
Data from 144 ChIP-Seq tracks from a single run of 24 samples. No advanced bioinformatics required thanks to the open-source data analysis pipeline. Efficient, consistent, and scalable allowing for larger cohort studies and longitudinal studies.
EpiFinder™ cNUC Key Differentials
Parallel Profiling of Multiple Epigenetic Marks
Analysis of multiple validated epigenetic marks simultaneously in a single workflow, tailored towards multiple therapeutical areas. Our selection includes but is not limited to H3K4me3, H3K27ac, H3K27me3, H3K9me3 and DNA methylation.
No Nucleosome Extraction Needed
Direct analysis of nucleosomes in plasma and serum preserves biological integrity, simplifies the process, and saves cost and time.
Unbiased Methylome Biomarkers Discovery
Genome-wide identification of DNA methylation signatures directly from samples, accelerating methylome biomarker discovery.
Reduced Cost Per Sample
Multiplexing significantly lowers both experimental and sequencing costs.
The EpiFinder™ cNUC Workflow
Do You Want To Read More?
To learn more, contact our experts at sales@epigenica.se
Our experts can help select validated epigenetic markers tailored to research areas including cancer, aging, and inflammation.
The EpiFinder™ cNUC is available as a kit or as a fully supported service tailored to your needs.